ICICI Direct: Natco Pharma Logs Stable Quarter; Next Growth Phase Hinges On New Ventures 
An employee scoops up tablet cores for inspection at a pharmaceutical plant. (Photographer Hannelore Foerster/Bloomberg)

ICICI Direct: Natco Pharma Logs Stable Quarter; Next Growth Phase Hinges On New Ventures 


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Natco Pharma Ltd.’s Q1 FY21 revenues grew 14.4% YoY to Rs 563 crore. Export formulations grew 13.8% YoY to Rs 274 crore.

Domestic formulations de-grew 23.4% YoY to Rs 126 crore as the oncology segment continued to be impacted by lower hospitalisation rate amid pandemic. Active pharmaceutical Ingredient (API) segment sales doubled YoY to Rs 144 crore.

Ebitda margins fell 849 basis points YoY to 30.4% due to significantly lower gross margin following a change in product mix towards margin dilutive products that was partly offset by lower employee cost and other expenditure.

Subsequently, Ebitda de-grew 10.6% YoY to Rs 171.1 crore. Net profit de-grew 14.2% YoY to Rs 122.8 crore.

Click on the attachment to read the full report:

ICICI Direct Natco Pharma Q1FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.